Answers are grounded in this paper and cite their sources.
Multiple sclerosis (MS) is a chronic, disabling disease of the central nervous system (CNS) that affects 2.8 million people worldwide (35.9 per 100 000 population). The symptoms and signs of disease result from plaques of CNS demyelination, presumably from autoimmune attack of the myelin sheath. In 1868, in a series of brilliant lectures, Jean-Martin Charcot at the Salpêtri ere Hospice in Paris pieced together the clinical, anatomical and pathophysiological features of a new disease entity associated with scl erose en plaques in the brain and spinal cord, a condition, which would later be translated into English as multiple sclerosis. Since this Victorian era description, a number of observations have supported the notion that MS may arise from an aberrant immune response to an unidentified infectious agent. These include the presence in > 90% of people with MS (PwMS) of oligoclonal bands of immunoglobulin G (IgG) in the cerebrospinal fluid (CSF), which are often also found in CNS infections, for example with bacterial, cryptococcal and tuberculous meningitis, viral encephalitis and neurosyphilis. However, oligoclonal bands in the CSF are also observed in patients with inflammation from systemic lupus erythematosus (SLE), neurosarcoidosis and traumatic brain injury. Several candidate infectious agents have been proposed over the years as the trigger for MS. These include human herpes family viruses such as human herpes virus 6 (HHV-6) and Epstein–Barr virus (EBV), coronaviruses and human endogenous retroviruses (HERVs). The leading candidate has been EBV, and this is supported by many studies providing epidemiological, immunological and virological evidence for a role for EBV in MS (summarised by Soldan and Lieberman). This evidence had been largely circumstantial until 2022 when a landmark paper established convincingly that EBV infection was necessary to cause MS. In an epic effort that exemplifies the power of mega cohorts in the age of big data, Bjornevik et al. longitudinally tracked 10 million US military personnel over 20 years to show that the risk of MS increased 32-fold after infection with EBV. The strength of this study lies not just in its scale, but also in the carefully designed questions and controls, which allowed the authors to draw such a powerful conclusion. However, EBV is ubiquitous and > 90% of the adult population worldwide is seropositive. The disconnect between the widespread prevalence of EBV and the infrequency of MS suggests that, while EBV may be necessary (Tier 1 of the Pender hypothesis), it is not sufficient to cause MS and there are multiple additional genetic and environmental factors involved in disease pathogenesis (Figure 1). In this Special Feature of Clinical & Translational Immunology, we have followed Charcot’s interdisciplinary example and pieced together a collection of reviews by virologists, neurologists, immunologists and genomicists to get some
No takes yet. Share an insight, caveat, or question.
Tri Giang Phan (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: